Effect of Tirzepatide on arrhythmic, major cardiovascular, and neurological outcomes in patients with type 2 diabetes: A systematic review and meta-analysis.

Wu R, Xing B, Zhou Z, Yu L, Wang H

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology17 Dec 2025Cited by 1 (Europe PMC)

PMID41402646DOI10.1007/s10072-025-08680-zPepBankPUB-41402646

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide was not associated with a significant increase in atrial fibrillation in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide was not linked to more atrial fibrillation.
Peptide
Tirzepatide
Outcome
No significant changeAtrial fibrillation risk
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
1.39 ratio
atrial fibrillation
Source sentences
Summary
Tirzepatide was not associated with a statistically significant increase in arrhythmic outcomes, including atrial fibrillation (AF) (RR 1.39, 95% CI 0.53 to 3.67) and atrial flutter (AFL) (RR 1.14, 95% CI 0.20 to 6.55).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve RCTs involving 10,615 patients with T2D were included.
Report a problemFND-4140264601
02HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide was not associated with a significant increase in atrial flutter in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide was not linked to more atrial flutter.
Peptide
Tirzepatide
Outcome
No significant changeAtrial flutter risk
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
1.14 ratio
atrial flutter
Source sentences
Summary
Tirzepatide was not associated with a statistically significant increase in arrhythmic outcomes, including atrial fibrillation (AF) (RR 1.39, 95% CI 0.53 to 3.67) and atrial flutter (AFL) (RR 1.14, 95% CI 0.20 to 6.55).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve RCTs involving 10,615 patients with T2D were included.
Report a problemFND-4140264602
03HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide showed no significant difference in acute myocardial infarction in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide was not linked to a different heart attack risk.
Peptide
Tirzepatide
Outcome
No significant changeAcute myocardial infarction risk
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
0.66 ratio
acute myocardial infarction
Source sentences
Summary
For major CV outcomes, no significant differences were observed for acute myocardial infarction (RR 0.66, 95% CI 0.38 to 1.17) or coronary artery disease (RR 0.62, 95% CI 0.32 to 1.18).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve RCTs involving 10,615 patients with T2D were included.
Report a problemFND-4140264603
04HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide showed no significant difference in coronary artery disease in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide was not linked to a different risk of coronary artery disease.
Peptide
Tirzepatide
Outcome
No significant changeCoronary artery disease risk
Study
n: not reported in source
Outcome group
Cardiovascular events · Cardiovascular
Studied dose
Dose not stated
Measurements
Risk ratio
0.62 ratio
coronary artery disease
Source sentences
Summary
For major CV outcomes, no significant differences were observed for acute myocardial infarction (RR 0.66, 95% CI 0.38 to 1.17) or coronary artery disease (RR 0.62, 95% CI 0.32 to 1.18).
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve RCTs involving 10,615 patients with T2D were included.
Report a problemFND-4140264604
05HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide significantly increased the risk of dizziness in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide was linked to more dizziness.
Peptide
Tirzepatide
Outcome
IncreaseDizziness risk
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Risk ratio
1.64 ratio
dizziness
Source sentences
Summary
Neurologically, tirzepatide significantly increased the risk of dizziness (RR 1.64, 95% CI 1.04 to 2.57), whereas the risks of headache (RR 1.00, 95% CI 0.65 to 1.55) and transient ischemic attack (RR 1.43, 95% CI 0.44 to 4.61) were not significant.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve RCTs involving 10,615 patients with T2D were included.
Report a problemFND-4140264605
06HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide showed no significant change in headache risk in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide was not linked to more headache.
Peptide
Tirzepatide
Outcome
No significant changeHeadache risk
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Risk ratio
1 ratio
headache
Source sentences
Summary
Neurologically, tirzepatide significantly increased the risk of dizziness (RR 1.64, 95% CI 1.04 to 2.57), whereas the risks of headache (RR 1.00, 95% CI 0.65 to 1.55) and transient ischemic attack (RR 1.43, 95% CI 0.44 to 4.61) were not significant.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve RCTs involving 10,615 patients with T2D were included.
Report a problemFND-4140264606
07HumanSystematic reviewSafety outcome
In adults with type 2 diabetes, tirzepatide showed no significant change in transient ischemic attack risk in a meta-analysis of randomized trials.
In plain wordsIn pooled trials of adults with type 2 diabetes, tirzepatide was not linked to more transient ischemic attacks.
Peptide
Tirzepatide
Outcome
No significant changeTransient ischemic attack risk
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Measurements
Risk ratio
1.43 ratio
transient ischemic attack
Source sentences
Summary
Neurologically, tirzepatide significantly increased the risk of dizziness (RR 1.64, 95% CI 1.04 to 2.57), whereas the risks of headache (RR 1.00, 95% CI 0.65 to 1.55) and transient ischemic attack (RR 1.43, 95% CI 0.44 to 4.61) were not significant.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve RCTs involving 10,615 patients with T2D were included.
Report a problemFND-4140264607
08HumanSystematic reviewSafety outcome
In a subgroup analysis of adults with type 2 diabetes aged 60 years or younger, tirzepatide was suggested to carry a higher dizziness risk.
In plain wordsIn pooled trials, the dizziness risk with tirzepatide seemed higher in people aged 60 or younger.
Peptide
Tirzepatide
Outcome
IncreaseDizziness risk in patients aged 60 years or younger
Study
n: not reported in source
Outcome group
Adverse events · Nervous system and cognition
Studied dose
Dose not stated
Source sentences
Summary
Subgroup analyses suggested higher dizziness risk in patients aged ≤ 60 years.
1 context sentence(design, population, supporting numbers)
Summary · context
Twelve RCTs involving 10,615 patients with T2D were included.
Report a problemFND-4140264608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:07 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.